A signal finding study of AEVI-001 in Autism Spectrum Disorders (ASD).
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Fasoracetam (Primary)
- Indications Pervasive child development disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors Aevi Genomic Medicine
- 09 Aug 2017 According to an Aevi Genomic Medicine media release, the company plans to initiate this trial in early 2018.
- 15 Mar 2017 New trial record
- 09 Mar 2017 According to an Aevi Genomic Medicine media release, company expects to have initial open-label responder data in 2H of 2017.